BPA Call #36C24126N0614

Adaptive Biotechnologies Awarded BPA Call for ClonoSEQ Testing at VA Health Centers

This award represents a supplemental blanket purchase agreement (BPA) call under an existing long-term BPA vehicle with Adaptive Biotechnologies Corporation, a leader in biotechnology specializing in advanced genomic diagnostic services. The contract focuses on providing ClonoSEQ testing, a cutting-edge genomic assay crucial for detecting and monitoring minimal residual disease in cancer patients. This testing service is vital for improving clinical decision-making and personalized treatment for veterans at the Boston and West Haven Department of Veterans Affairs Health Care Systems. The scope includes delivering precise and timely ClonoSEQ testing to support veteran patient care through genomic insights. This procurement is made as a direct BPA call, continuing the strategic relationship established in the base BPA awarded earlier without undergoing competitive bidding, highlighting the VA's reliance on Adaptive Biotechnologies' specialized capabilities. The period of performance spans a one-year interval, ensuring continued access to critical diagnostic testing. This contract further reinforces the VA's commitment to integrating innovative medical technologies in healthcare delivery for veterans, supporting precision medicine initiatives that enhance treatment outcomes.

Description

CLONOSEQ TESTING FOR BOSTON AND WEST HAVEN VA HCS

View original record